AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 11 min read$CMMB

Mor George Adi purchased $20K of CMMB

Mor George Adi (Chief Executive Officer) purchased 9,804 shares of Chemomab Therapeutics Ltd. (CMMB) at an average of $2.07 ($2.05–$2.08) across 2 trades on 2026-05-29.

Original reporting
SEC EDGAR · Mor George Adi
Published Jun 1, 2026, 11:33 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:46 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CMMB
Neutral
low confidence
Mentioned
$CMMB
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CMMBNeutralLow
01

Why it matters

The purchase is modest and unlikely to affect CMMB's share price materially.

02

Market read

Routine insider purchase with limited trading relevance.

03

What to watch

Potential upcoming clinical data releases may make any insider activity more significant.

Relevance 4/10Novelty 4/10Timing: post‑market filing on June 1

Background

Form 4 filings disclose insider transactions; investors monitor them for signals.

Company-level read

Ticker impact

$CMMBNeutralLow confidence
Context

CEO Mor George Adi bought 9,804 shares for $20,246, raising his stake to 139,131 shares.

Expected impact

slight upward pressure as market prices in insider buying

Evidence & confidence

The transaction size (~$20k) is trivial for a public float, unlikely to move price materially.

Market effects

Sector

Minimal; reflects typical insider activity in biotech sector.

Regional

None; company is US‑listed with limited trading volume.

Global

Low; no broader market effect.

Counterpoint

What could challenge this read

Insider buying could be a routine portfolio rebalancing rather than a bullish signal.

Key entities

  • Company
    Chemomab Therapeutics Ltd.

    Biotech firm developing therapeutic candidates.

  • Person
    Mor George Adi

    Chief Executive Officer of Chemomab Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CMMB insider trading history →

Related articles

JUL 8
$CMMBMedAI 8/10

Chemomab Therapeutics, Scipher Medicine Announce Merger Agreement, Stock Down In Pre-Market

Chemomab Therapeutics (CMMB) and Scipher Medicine agreed to merge, forming a Nasdaq-listed company trading as SCIP. The combined firm will advance nebokitug, an anti-CCL24 antibody, into a Phase 2 rheumatoid arthritis trial. Chemomab holders expected to own ~32% and Scipher ~68%, with contingent value rights. About $30M new funding; cash expected to fund through H2 2028. Deal expected to close Q4 2026; CMMB down to $2.39 pre-market.

rttnews.com6 min
JUL 8
$CMMBHighAI 9/10

Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis

Chemomab Therapeutics (Nasdaq: CMMB) and Scipher Medicine (Nasdaq-bound) announced a definitive merger in a stock deal, with the combined company to trade on Nasdaq as Scipher Medicine Corporation under ticker “SCIP”. The focus will be advancing nebokitug, an anti-CCL24 antibody, into a Phase 2 RA trial, with topline results expected in H1 2028. A $30M private placement is planned, valuing the deal at $150M pre-placement, and cash is expected to fund operations into H2 2028.

manilatimes.net3 min
JUL 8
$CMMBMedAI 9/10

Chemomab Therapeutics Ltd.: Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis

Chemomab Therapeutics (Nasdaq: CMMB) and Scipher Medicine (Nasdaq-bound) announced a definitive merger to combine in a stock deal, with the combined company to trade on Nasdaq as Scipher Medicine Corporation under ticker SCIP. The focus is advancing nebokitug, an anti-CCL24 antibody, into a Phase 2 RA trial using Scipher’s PrismRA test. A $30M private placement supports operations into H2 2028; Phase 2 readout expected H1 2028. Valuation cited at $150M pre-merger.

finanznachrichten.de6 min
OCT 7
$LWAYLow

Divisadero Street Capital Management, LP (Zolezzi William) purchased $2.2M of LWAY (indirect holdings)

Divisadero Street Capital Management, LP purchased 103,684 indirectly-held shares of Lifeway Foods, Inc. (LWAY) at an average of $20.92 ($20.80–$21.09, $2.17M total) across 3 trades over 2026-10-02 to 2026-10-06. Filed jointly with Divisadero Street Partners GP, LLC (10% owner), Zolezzi William (10% owner), Divisadero Street Partners, L.P. (10% owner) and Divisadero Street Capital, LLC (10% owner).

SEC EDGAR1 min